Adenoviral gene transfer of viral interleukin-10 protects cerebrovascular impairment induced by lysophosphatidylcholine

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 175-181

  Kang, Hui ^a   Yang, Peng Yuan ^a   Rui, Yao Cheng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adhesion molecules; Cerebrovascular dysfunction; Lysophosphatidylcholine; Viral interleukin 10

Indexed keywords

ACETYLCHOLINE; ADENOVIRUS VECTOR; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VIRAL INTERLEUKIN 10; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASILAR ARTERY; CELL ADHESION; CELL CULTURE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DOG; DRUG EFFICACY; ENDOTHELIUM CELL; GENE TRANSFER; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BASILAR ARTERY; CELL ADHESION; CELL LINE; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; DOGS; ENDOTHELIUM, VASCULAR; GENE TRANSFER TECHNIQUES; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; LYSOPHOSPHATIDYLCHOLINES; MICE; MICROCIRCULATION; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1; VASOCONSTRICTION;

EID: 37649005382     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.047     Document Type: Article

References (22)

1. Blankenberg S., Barbaux S., and Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2 (2003) 191-203
2. Blum A., Khazim K., Merei M., Peleg A., Blum N., and Vaispapir V. The Stroke Trial can we predict clinical outcome of patients with ischemic stroke by measuring soluble cell adhesion molecules (CAM)?. Eur. Cytokine Netw. 4 (2006) 295-298
3. Brevetti G., Schiano V., and Chiariello M. Cellular adhesion molecules and peripheral arterial disease. Vasc. Med. 1 (2006) 39-47
4. Chan H., Lougheed M., Laher I., and Steinbrecher U.P. Oxidized low-density lipoprotein inhibits endothelium-dependent vasodilation by an antioxidant-sensitive, lysophosphatidylcholine-independent mechanism. J. Cardiovasc. Pharmacol. 6 (2003) 856-865
5. Chen L., Liang B., Froese D.E., Liu S., Wong J.T., Tran K., Hatch G.M., Mymin D., Kroeger E.A., Man R.Y., and Choy P.C. Oxidative modification of loss density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J. Lipid Res. 3 (1997) 546-553
6. Frijns C.J., and Kappelle L.J. Inflammatory cell adhesion molecules in ischemic cerebrovasular disease. Stroke 8 (2002) 2115-2122
7. Harrod K.S., Trapnell B.C., Otake K., Korfhagen T.R., and Whitsett J.A. SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. Am. J. Physiol. 3 Pt 1 (1999) L580-L588
8. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinants adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 5 (1998) 2509-2514
9. Inoue N., Takeshita S., Gao D., Ishida T., Kawashima S., Akita H., Tawa R., Sakurai H., and Yokoyama M. Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells. Atherosclerosis 1 (2001) 45-52
10. Kaya Z., Dohmen K.M., Wang Y., Schlichting J., Afanasyeva M., Leuschner F., and Rose N.R. Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J. Immunol. 4 (2002) 1552-1556
11. Ley K., and Huo Y. VCAM-1 is critical in atherosclerosis. J. Clin. Invest. 10 (2001) 1209-1210
12. Libby P. Inflammation in atherosclerosis. Nature 6917 (2002) 868-874
13. Minter R.M., Rectenwald J.E., Fukuzuka K., Tannahill C.L., La Face D., Tsai V., Ahmed I., Hutchins E., Moyer R., Copeland III E.M., and Moldawer L.L. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. J. Immunol. 1 (2000) 443-451
14. Minter R.M., Ferry M.A., Rectenwald J.E., Bahjat F.R., Oberholzer A., Oberholzer C., La Face D., Tsai V., Ahmed C.M., Hutchins B., Copeland III E.M., Ginsberg H.S., and Moldawer L.L. Extended lung expression and increased tissue localization of viral IL-10 with adenoviral gene therapy. Proc. Natl. Acad. Sci. U. S. A. 1 (2001) 277-282
15. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. (2001) 683-765
16. Ooboshi H., Ibayashi S., Shichita T., Kumai Y., Takada J., Ago T., Arakawa S., Sugimori H., Kamouchi M., Kitazono T., and Iida M. Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 7 (2005) 913-919
17. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 2 (1999) 115-126
18. Rothoerl R.D., Schebesch K.M., Kubitza M., Woertgen C., Brawanski A., and Pina A.L. ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic deficits. Cerebrovasc. Dis. 2-3 (2006) 143-149
19. van Roon J.A., Lafeber F.P., and Bijlsma J.W. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 1 (2001) 3-12
20. Verbeuren T.J. Experimental models of thrombosis and atherosclerosis. Therapies 5 (2006) 379-387
21. Yamakawa T., Tanaka S., Yamakawa Y., Kamei J., Numaguchi K., Motley E.D., Inagami T., and Eguchi S. Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 5 (2002) 752-758
22. Zhu Y., Lin J.H., Liao H.L., Verna L., and Stemerman M.B. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim. Biophys. Acta 1 (1997) 93-98